Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2019

Shelley Wood

July 31, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Michael O'Riordan

March 13, 2019

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Shelley Wood

February 12, 2019

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

Advertisement

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Recurrent Events Common Among Young Patients With CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

TCTMD’s Top 10 Most Popular Stories for July 2019

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Could PET Imaging Be the ‘Game Changer’ for Detecting and Predicting Bioprosthetic Valve Degeneration?

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content